Sensitivity analysis revealed LB-100 affected 548 cancer cell lines broadly.<h4>Conclusion</h4><i>PPP2CA</i> represents a promising therapeutic vulnerability in CML, supported by both strong dependency and consistent expression in myeloid models, while BRAF showed limited relevance outside mutation-driven cancers. The gene discussed is BRAF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.